Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | Molecular Autism

Fig. 2

From: Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome

Fig. 2

Western blot analysis demonstrating the capacity of indenoisoquinoline derivatives to increase paternal UBE3A-YFP at the protein level in cultured neurons from Ube3am+/pYFP mice. a Immunoblot and quantification of UBE3A-YFP levels normalized to actin in cultured neurons from wildtype (WT) or Ube3am+/pYFP mice treated with DMSO (0.1% vehicle control), topotecan (0.3 μM), indotecan (0.3 μM), or indimitecan (0.3 μM) (n = 3/group, *p < 0.05). b Immunoblots and quantification of UBE3A-YFP levels normalized to actin in cultured neurons from wildtype (WT) or Ube3am+/pYFP mice treated with DMSO (0.1% vehicle control), topotecan (0.3 μM), DB-IV-58 (0.3 μM), or DB-V-37 (0.3 μM) (n = 3/group, *p < 0.05)

Back to article page

Molecular Autism

ISSN: 2040-2392